Docetaxel added to androgen deprivation therapy (ADT) was the most cost-effective first-line regimen for patients with ...
Investing.com-- Shares of Telix Pharmaceuticals (ASX:TLX) jumped on Tuesday after the company reported positive results from ...
Please provide your email address to receive an email when new articles are posted on . Men with metastatic castration-resistant prostate cancer had significantly longer OS with docetaxel rechallenge ...
Johnson & Johnson (NYSE:JNJ) is one of the 10 best stocks to invest in during a recession. On February 26, 2026, Johnson & ...
The ARASAFE study showed that a 50 mg/m2 biweekly docetaxel regimen reduced severe side effects compared to the standard 75 mg/m2 triweekly regimen in mHSPC patients. The experimental regimen resulted ...
Johnson & Johnson (NYSE:JNJ) today announced preliminary results from a Phase 1b study evaluating pasritamig (JNJ-78278343), a first-in-class bispecific T-cell engaging antibody, in combination with ...
Pertuzumab Retreatment for Human Epidermal Growth Factor Receptor 2–Positive Locally Advanced/Metastatic Breast Cancer (PRECIOUS Study): Final Overall Survival Analysis The standard of care for ...
Adding pembrolizumab to docetaxel failed to improve survival in metastatic castration-resistant prostate cancer. Overall survival was 19-20 months regardless of treatment arm, even in patients with PD ...
Florida Cancer Specialists & Research Institute, LLC (FCS) advances genitourinary cancer treatment through participation at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results